Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review, 28518 [2014-11364]

Download as PDF 28518 Federal Register / Vol. 79, No. 95 / Friday, May 16, 2014 / Notices Prevention and the Agency for Toxic Substances and Disease Registry. DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES Gary J. Johnson, Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. Centers for Disease Control and Prevention Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review The meeting announced below concerns Managing Epilepsy Well (MEW) Network Coordinating Center, Special Interest Projects (SIP)14–006; Managing Epilepsy Well (MEW) Collaborating Center, SIP14–007; and Testing New Communication Strategies to Improve Attitudes Toward Epilepsy, SIP14–008, Panel H, initial review. In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting: The meeting announced below concerns Mycoplasma genitalium Among Women Attending Family Planning and STD Clinics in the US: Assessing Burden, Risk Factors, Sequelae, Antibiotic Resistance, and Association with Treatment Outcomes, Special Interest Project (SIP)14–033; and Prospective Study of Immune Response to Chlamydial Infection to Inform Development of Rational Prevention Strategies, SIP14–034, Panel I, initial review. In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting: [FR Doc. 2014–11358 Filed 5–15–14; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review EMCDONALD on DSK67QTVN1PROD with NOTICES The meeting announced below concerns Research on Integration of Injury Prevention in Health Systems, Funding Opportunity Announcement (FOA) CE14–004, initial review. In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting: Time and Date: 12:00 p.m.–7:00 p.m. EDT, June 3, 2014 (Closed). Place: This meeting will be held by teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463. Matters for Discussion: The meeting will include the initial review, discussion, and evaluation of applications received in response to ‘‘Research on Integration of Injury Prevention in Health Systems, FOA CE14–004.’’ Contact Person for More Information: Jane Suen, Dr.P.H., M.S., Scientific Review Officer, CDC, 4770 Buford Highway NE., Mailstop F63, Atlanta, Georgia 30341–3724, Telephone: (770) 488–4281. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. Time and Date: 10:00 a.m.–5:00 p.m., June 3, 2014 (Closed). Place: Teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463. Matters for Discussion: The meeting will include the initial review, discussion, and evaluation of applications received in response to ‘‘Managing Epilepsy Well (MEW) Network Coordinating Center, SIP14–006; Managing Epilepsy Well (MEW) Network Collaborating Center, SIP14–007; and Testing New Communication Strategies to Improve Attitudes Toward Epilepsy, SIP14–008, Panel H’’, initial review. Contact Person for More Information: M. Chris Langub, Ph.D., Scientific Review Officer, CDC, 4770 Buford Highway NE., Mailstop F–80, Atlanta, Georgia 30341, Telephone: (770) 488–3585, EEO6@cdc.gov. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Gary J. Johnson, Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. Time and Date: 2:00 p.m.–6:00 p.m., June 4, 2014 (Closed). Place: Teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463. Matters for Discussion: The meeting will include the initial review, discussion, and evaluation of applications received in response to ‘‘Mycoplasma genitalium Among Women Attending Family Planning and STD Clinics in the US; Assessing Burden, Risk Factors, Sequelae, Antibiotic Resistance, and Association with Treatment Outcomes, SIP14–033; and Prospective Study of Immune Response to Chlamydial Infection to Inform Development of Rational Prevention Strategies, SIP14–034, Panel I, initial review.’’ Contact Person for More Information: M. Chris Langub, Ph.D., Scientific Review Officer, CDC, 4770 Buford Highway NE., Mailstop F–80, Atlanta, Georgia 30341, Telephone: (770) 488–3585, EEO6@cdc.gov. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. [FR Doc. 2014–11359 Filed 5–15–14; 8:45 am] [FR Doc. 2014–11352 Filed 5–15–14; 8:45 am] Gary J. Johnson, Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. BILLING CODE 4163–18–P [FR Doc. 2014–11364 Filed 5–15–14; 8:45 am] BILLING CODE 4163–18–P BILLING CODE 4163–18–P VerDate Mar<15>2010 20:00 May 15, 2014 Jkt 232001 PO 00000 Frm 00046 Fmt 4703 Sfmt 9990 E:\FR\FM\16MYN1.SGM 16MYN1

Agencies

[Federal Register Volume 79, Number 95 (Friday, May 16, 2014)]
[Notices]
[Page 28518]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-11364]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Disease, Disability, and Injury Prevention and Control Special 
Emphasis Panel (SEP): Initial Review

    The meeting announced below concerns Mycoplasma genitalium Among 
Women Attending Family Planning and STD Clinics in the US: Assessing 
Burden, Risk Factors, Sequelae, Antibiotic Resistance, and Association 
with Treatment Outcomes, Special Interest Project (SIP)14-033; and 
Prospective Study of Immune Response to Chlamydial Infection to Inform 
Development of Rational Prevention Strategies, SIP14-034, Panel I, 
initial review.
    In accordance with Section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the aforementioned meeting:

    Time and Date: 2:00 p.m.-6:00 p.m., June 4, 2014 (Closed).
    Place: Teleconference.
    Status: The meeting will be closed to the public in accordance 
with provisions set forth in Section 552b(c)(4) and (6), Title 5 
U.S.C., and the Determination of the Director, Management Analysis 
and Services Office, CDC, pursuant to Public Law 92-463.
    Matters for Discussion: The meeting will include the initial 
review, discussion, and evaluation of applications received in 
response to ``Mycoplasma genitalium Among Women Attending Family 
Planning and STD Clinics in the US; Assessing Burden, Risk Factors, 
Sequelae, Antibiotic Resistance, and Association with Treatment 
Outcomes, SIP14-033; and Prospective Study of Immune Response to 
Chlamydial Infection to Inform Development of Rational Prevention 
Strategies, SIP14-034, Panel I, initial review.''
    Contact Person for More Information: M. Chris Langub, Ph.D., 
Scientific Review Officer, CDC, 4770 Buford Highway NE., Mailstop F-
80, Atlanta, Georgia 30341, Telephone: (770) 488-3585, EEO6@cdc.gov.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining 
to announcements of meetings and other committee management 
activities, for both the Centers for Disease Control and Prevention 
and the Agency for Toxic Substances and Disease Registry.

Gary J. Johnson,
Acting Director, Management Analysis and Services Office, Centers for 
Disease Control and Prevention.
[FR Doc. 2014-11364 Filed 5-15-14; 8:45 am]
BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.